CRA INTERNATIONAL, INC.
CRA International reported Q2 2026 record quarterly revenue, up 12.8% year over year, with 95% of its portfolio contributing. Full-year 2026 revenue guidance was raised to $805 million to $820 million, with non-GAAP EBITDA margin of 12.0% to 13.0%. The company expanded its $400 million credit facility and returned $31.4 million to shareholders.
CRA International (NASDAQ:CRAI) reported Q2 CY2026 revenue of $210.8 million, up 12.8% year over year, exceeding Wall Street’s revenue estimate by 6%, according to the company and analysts. Non-GAAP adjusted EPS was $2.16, up from $1.88 a year earlier and 0.6% above consensus. The stock rose 1.9% to $179.96 after results.
CRA INTERNATIONAL, INC. (CRAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 craiq2-20268xkexx992xcfore.htm EX-99.2 Document Exhibit 99.2 CHARLES RIVER ASSOCIATES (CRA) SECOND QUARTER FISCAL YEAR 2026 EARNINGS ANNOUNCEMENT PREPARED CFO REMARKS CRA is providing these prepared remarks by CFO Eric Nierenberg in combination with its press release. T
Over the past 7 days, alphai's AI scored 3 news stories mentioning CRAI (CRA INTERNATIONAL, INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent CRAI coverage spans insider activity, earnings and corporate actions.
In the last 30 days, CRAI insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($36K). The most active reporter was Tookes Heather with 2 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Guidance increase plus margin guidance and utilization/headcount commentary create a near-term earnings model reset for CRAI.
The beat on revenue and modestly above-consensus adjusted EPS supports near-term upside bias, but guidance deceleration tempers follow-through.
The filing provides fresh quarterly financial datapoints and operating metrics (utilization, DSO, cash, revolver borrowings) that can drive near-term earnings revisions and sentiment.
Routine annual meeting voting outcomes with no new financial guidance or corporate action beyond governance items.
CRA is a service provider to a biotech’s commercialization planning; the news is incremental and unlikely to be material to CRA’s financials.
alphai scores every news story that mentions CRAI with an AI model for sentiment and relevance, and aggregates insider trades from CRA INTERNATIONAL, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CRA International reported Q2 2026 record quarterly revenue, up 12.8% year over year, with 95% of its portfolio contributing. Full-year 2026 revenue guidance was raised to $805 million to $820 million, with non-GAAP EBITDA margin of 12.0% to 13.0%. The company expanded its $400 million credit facility and returned $31.4 million to shareholders.
6 min readCRA International (NASDAQ:CRAI) reported Q2 CY2026 revenue of $210.8 million, up 12.8% year over year, exceeding Wall Street’s revenue estimate by 6%, according to the company and analysts. Non-GAAP adjusted EPS was $2.16, up from $1.88 a year earlier and 0.6% above consensus. The stock rose 1.9% to $179.96 after results.
4 min readCRA INTERNATIONAL, INC. (CRAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 craiq2-20268xkexx992xcfore.htm EX-99.2 Document Exhibit 99.2 CHARLES RIVER ASSOCIATES (CRA) SECOND QUARTER FISCAL YEAR 2026 EARNINGS ANNOUNCEMENT PREPARED CFO REMARKS CRA is providing these prepared remarks by CFO Eric Nierenberg in combination with its press release. T
4 min readCRA INTERNATIONAL, INC. (CRAI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001053706 0001053706 2026-07-16 2026-07-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
2 min readBriaCell Therapeutics (Nasdaq: BCTX, BCTXL; TSX: BCT) said it hired Charles River Associates (CRA) and Kaleio to support commercial strategy, market-access evaluation, and brand planning for Bria-IMT. Bria-IMT is in an ongoing pivotal Phase 3 study for metastatic breast cancer and is not yet approved.
3 min readStocks including Rogers (ROG, +3.5%), DXC (DXC, +4.2%) and CRA (CRAI, +3.1%) rose after prospects of a US-Iran peace deal reduced a geopolitical risk premium, easing corporate spending expectations. The article links the move to falling rate-hike odds (to 36%) and lower credit tightening. It notes DXC is $9.15, down 35% YTD.
4 min readMaleh Paul A (PRESIDENT AND CEO) sold 1,100 shares of CRA INTERNATIONAL, INC. (CRAI) at $142.17 ($0.16M total) on 2026-06-03 under a Rule 10b5-1 trading plan.
1 min readMaleh Paul A (PRESIDENT AND CEO) sold 319 shares of CRA INTERNATIONAL, INC. (CRAI) at $136.86 on 2026-06-03 under a Rule 10b5-1 trading plan.
2 min readMaleh Paul A (PRESIDENT AND CEO) sold 5,581 shares of CRA INTERNATIONAL, INC. (CRAI) at $135.99 ($0.76M total) on 2026-06-03 under a Rule 10b5-1 trading plan.
1 min readMaleh Paul A (PRESIDENT AND CEO) sold 500 shares of CRA INTERNATIONAL, INC. (CRAI) at $134.48 on 2026-06-03 under a Rule 10b5-1 trading plan.
1 min read
